Access the full text.
Sign up today, get DeepDyve free for 14 days.
Baker LH Ratanatharathorn V (1979)
Mitomycin C, Current Status and New Developments
D. Karlin, J. Stroehlein (1980)
RASH, NEPHRITIS, HYPERTENSION, AND HÆMOLYSIS IN PATIENT ON 5-FLUOROURACIL, DOXORUBICIN, AND MITOMYCIN-CThe Lancet, 316
Newman CD Jones BG (1980)
Intravesicular haemolysis and renal impairment after blood transfusion in two patients on long-term 5-Fluorouracil and Mitomycin C.Lancet, 1
W. Hanna, S. Krauss, R. Regester, W. Murphy (1981)
Renal disease after mitomycin c therapyCancer, 48
B. Kressel, K. Ryan, A. Duong, J. Berenberg, P. Schein (1981)
Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinomaCancer, 48
M. Matsuyama, K. Suzumori, Taka-aki Nakamura (1964)
Induction of Hydronephrosis by Prolonged Intraperitoneal Injections of Sub-toxic Dose of Mitomycin C in MiceNature, 202
S. Krauss, T. Sonoda, A. Solomon (1979)
Treatment of advanced gastrointestinal cancer with 5‐fluorouracil and mitomycin CCancer, 43
MD LIU, MD MIITELMAN, M. SPROUL, M. ELIAS, Roswell Park (1971)
Renal toxicity in man treated with mitomycin CCancer, 28
B. Spargo, A. Seymour, N. Ordóñez (1980)
Renal biopsy pathology, with diagnostic and therapeutic implications
K. Rumpf, J. Rieger, P. Lankisch, H.W.V Heyden, G. Nagel, F. Scheler (1980)
MITOMYCIN-INDUCED HAEMOLYSIS AND RENAL FAILUREThe Lancet, 316
K. Lempert (1980)
HÆMOLYSIS AND RENAL IMPAIRMENT SYNDROME IN PATIENTS ON 5-FLUOROURACIL AND MITOMYCIN-CThe Lancet, 316
F. Philips, H. Schwartz, S. Sternberg (1960)
Pharmacology of mitomycin C. I. Toxicity and pathologic effects.Cancer research, 20
Mutsushi Matsuyama, Kaoru Suzumori, Takaaki Nakamura (1964)
BIOLOGICAL STUDIES OF ANTICANCER AGENTS. I. EFFECTS OF PROLONGED INTRAPERITONEAL INJECTIONS OF MITOMYCIN C ON THE URINARY ORGANS.The Journal of urology, 92
S. Gulati, P. Sordillo, S. Kempin, L. Reich, G. Magill, E. Scheiner, B. Clarkson (1980)
Microangiopathic hemolytic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5‐fluorouracilCancer, 45
Bradner WT: Mitomycin C Crooke ST (1976)
A review.Cancer Treat Rev, 3
Abstract • Renal failure due to mitomycin chemotherapy is a poorly appreciated entity often associated with microangiopathic hemolytic anemia. We describe a 45-year-old man in whom renal failure and anemia developed, without evidence of hemolysis, five months after beginning chemotherapy with mitomycin, fluorouracil, and doxorubicin hydrochloride. A biopsy specimen taken from the patient's kidney showed fibrin thrombi in two of 18 glomeruli and in several small arteries. The patient's condition required institution of maintenance dialysis. Similar reports from the literature are reviewed. (Arch Intern Med 1983;143:803-807) References 1. Krauss S, Sonada T, Soloman A: Treatment of advanced gastrointestinal cancer with 5-Fluorouracil and Mitomycin C. Cancer 1979;43:1598-1603.Crossref 2. Gulati SC, Sordillo P, Kempin S, et al: Microangiopathic hemolytic anemia observed after treatment of epidermoid carcinoma with Mitomycin C and 5-Fluorouracil. Cancer 1980;45:2252-2257.Crossref 3. Jones BG, Newman CD, Fielding JW, et al: Intravesicular haemolysis and renal impairment after blood transfusion in two patients on long-term 5-Fluorouracil and Mitomycin C. Lancet 1980;1:1275-1276.Crossref 4. Lempert KD: Haemolysis and renal impairment syndrome in patients on 5-Fluorouracil and Mitomycin C. Lancet 1980;2:369-370.Crossref 5. Kressel BR, Ryan KP, Duong AT, et al: Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma. Cancer 1981;48:1738-1745.Crossref 6. Rumpf KW, Rieger J, Lankisch PG, et al: Mitomycin-induced haemolysis and renal failure. Lancet 1980;2:1037-1038.Crossref 7. Crooke ST, Bradner WT: Mitomycin C: A review. Cancer Treat Rev 1976;3:121-139.Crossref 8. Phillips FS, Schwartz HS, Sternbert SS: Pharmacology of Mitomycin C: I. Toxicity and pathologic effects. Cancer Res 1960;20:1344-1361. 9. Matsuyama M, Suzumori K, Nakamura T: Biological studies on anticancer agents: I. Effects of prolonged intraperitoneal injections of Mitomycin C on the urinary organs. J Urol 1964;92:618-620. 10. Matsuyama M, Suzumori K, Nakamura T: Induction of hydronephrosis by prolonged intraperitoneal injections of subtoxic dose of Mitomycin C in mice. Nature 1964;202:99-100.Crossref 11. Liu K, Mittelman A, Sproul EE, et al: Renal toxicity in man treated with Mitomycin C. Cancer 1971;28:1314-1320.Crossref 12. Ratanatharathorn V, Baker LH, Cadnapaphorchai P, et al: Clinical and pathological study of Mitomycin C nephrotoxicity , in Carter SK, Crooke ST (eds): Mitomycin C, Current Status and New Developments . New York, Academic Press, 1979, pp 219-229. 13. Hanna WT, Krauss S, Regester RF, et al: Renal disease after Mitomycin C therapy. Cancer 1981;48:2583-2588.Crossref 14. Spargo BH, Seymour AE, Ordonez NG: Renal Biopsy Pathology With Diagnostic and Therapeutic Implications . New York, John Wiley & Sons Inc, 1980, pp 266-284. 15. Karlin DA, Stroehlein JR: Rash, nephritis, hypertension and haemolysis in patients on 5-Fluorouracil, doxorubicin and Mitomycin C. Lancet 1980;2:534-535.Crossref
Archives of Internal Medicine – American Medical Association
Published: Apr 1, 1983
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.